The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.

By G. Guthrie, K. Charles, C. Roxburgh, P. Horgan, D. McMillan, S. Clarke. Critical reviews in oncology/hematology, 2013

1,495 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis (2017, background): “The presence of an elevated peripheral neutrophil-to-lymphocyte (NLR) ratio, an indicator of systemic inflammation, has been recognized as a poor prognostic factor in various cancers [3].”
Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? (2018, background): “In general, the blood NLR is high in patients with more advanced or aggressive cancers (Guthrie et al., 2013), and correlates with poor survival of patients with many solid tumors (Paramanathan et al., 2014; Templeton et al., 2014).”
Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 (2020, neutral): “[2] [3] [4] [5] A recent research has exhibited that severe cases of COVID-19 tended to have higher NLR. 6 Whether NLR could be an independent predictor of mortality in hospitalized COVID-19 patients needs to be further elucidated.”
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “The tumor-induced systemic inflammatory response leads to alterations of peripheral blood white blood cells [258].”